Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: James J Ciullo, MBA
- Phone Number: 6302512873
- Email: jay@lidopatch.com
Study Contact Backup
- Name: Eric Castro, MD
- Phone Number: 773-771-4160
- Email: jedc269@yahoo.com
Study Locations
-
-
Illinois
-
Barrington, Illinois, United States, 60010
- Recruiting
- Advocate Good Sheppard Hospital
-
Contact:
- Eric Castro, MD
- Phone Number: 773-771-4160
- Email: jedc269@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of back pain
- Diagnosis of arthritis
Exclusion Criteria:
- Pregnancy or expected pregnancy in the next three months
- Allergic to any lidocaine, menthol and methylparaben
- No reliable access to the internet
- Baseline average pain intensity of 1,2,9 or 10 on a scale of 0-to 10.
- Pain on the area of the body not conducive to patch therapy (eg fingers, toes etc)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Lidocaine5% v Lidocaine3.6%,Menthol1.25%
Daily patch Q12 followed by Q12 of no patch
|
10cmx 14 cm transdermal patch sealed in its own pouch
Other Names:
10cmx 14 cm transdermal patch sealed in its own pouch
Other Names:
|
|
Placebo Comparator: Lidocaine 3.6%, menthol 1.25% v placebo
Daily patch Q12 followed by Q12 of no patch
|
10cmx 14 cm transdermal patch sealed in its own pouch
Other Names:
patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy comparison of lidocaine 5% and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale
Time Frame: Day ten
|
Endpoint is a non-inferiority statistical comparison.
Comparison is based off of analysis of identical questionnaires administered at baseline and day ten
|
Day ten
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale
Time Frame: Day ten
|
Statistical superiority sought for lidocaine 3.6%,menthol 1.25% compared to placebo.
Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.
|
Day ten
|
|
Efficacy comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale
Time Frame: Day 10
|
Statistical superiority sought for lidocaine 3.6%,menthol 1.25% compared to placebo.
Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.
|
Day 10
|
|
Side effect comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale
Time Frame: Day 10
|
Endpoint is a non-inferiority statistical comparison.
Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.
|
Day 10
|
|
Side effect comparison of lidocaine 5% and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale
Time Frame: Day 10
|
Endpoint is a non-inferiority statistical comparison.
Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.
|
Day 10
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Back Pain
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Dermatologic Agents
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Antipruritics
- Lidocaine
- Menthol
Other Study ID Numbers
Other Study ID Numbers
- 527-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.